United States Patent 8,877,776: Scope, Claim Construction, and Landscape for Crystalline “Form N-2”
What does US 8,877,776 actually claim?
US 8,877,776 claims a specific active pharmaceutical ingredient (API) salt form: N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (L)-malate, limited to a defined crystalline polymorph “Form N-2”. The claims then extend to (1) formulations and (2) therapeutic methods in thyroid cancer and glioblastoma, with a sub-scope for medullary thyroid cancer.
The claim set you provided is directed to polymorph-specific protection, not broad chemical genus protection. The scope is anchored to three alternative identification standards for Form N-2: solid-state 13C NMR, XRPD/ powder X-ray diffraction, and an XRPD pattern substantially matching a referenced figure.
Independent claim scope (Claim 1): crystalline Form N-2 only
Claim 1 is a product claim with multiple constraints:
-
Molecular identity (fixed)
- Compound:
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (L)-malate
- It is specifically the (L)-malate salt.
-
Polymorph restriction (fixed)
- The salt must be in crystalline Form N-2.
-
Form characterization gates (open-ended “at least one of”)
- Form N-2 is “characterized by at least one” of the following analytical criteria.
Claim 1 analytical gates for “Form N-2”
(i) Solid-state 13C NMR criterion
- A solid state 13C NMR spectrum has four or more peaks selected from this list, each at ±0.2 ppm, including at least four peaks among:
- 23.0, 25.9, 38.0, 41.7, 69.7, 102.0, 122.5, 177.3, 179.3, 180.0, 180.3 (ppm)
(Claim 1, part (i) per provided text.)
(ii) XRPD numeric criterion (CuKα) at room temperature
- XRPD has two anchor peaks:
- 20.9 ± 0.2° 2θ
- 21.9 ± 0.2° 2θ
- Plus two or more additional peaks selected from:
- 6.4 ± 0.2°
- 9.1 ± 0.2°
- 12.0 ± 0.2°
- 12.8 ± 0.2°
- 13.7 ± 0.2°
- 17.1 ± 0.2°
- 22.6 ± 0.2°
- 23.7 ± 0.2°
- Measurement occurs at room temperature.
(Claim 1, part (ii) per provided text.)
(iii) XRPD “substantially in accordance with FIG. 8”
- The XRPD pattern is “substantially in accordance with the pattern shown in FIG. 8.”
(Claim 1, part (iii) per provided text.)
Dependent claims scope
Claim 2 (formulation)
- A pharmaceutical composition comprising:
- the Claim 1 Form N-2 (L)-malate salt and
- a pharmaceutically acceptable excipient.
(Claim 2 per provided text.)
This is a standard formulation dependent claim. It does not add new composition limits other than the Form N-2 constraint from Claim 1.
Claims 3 and 4 (medical use)
- Claim 3: treating thyroid cancer by administering the crystalline Form N-2 salt.
- Claim 4: treating glioblastoma by administering the crystalline Form N-2 salt.
(Claims 3 and 4 per provided text.)
Both are medical-use method-of-treatment claims tightly tied to the same polymorph.
Claim 5 (sub-type)
- Thyroid cancer is limited to medullary thyroid cancer.
(Claim 5 per provided text.)
How broad is the protection in practice?
Claim 1 is broad on identity of Form N-2 validation, narrow on the polymorph itself
- Broadest element: Claim 1 includes multiple analytical criteria and allows a Form to qualify via “at least one” of (i), (ii), or (iii).
- Narrowest element: the product must be the crystalline polymorph “Form N-2” of a single specific salt.
From an enforcement standpoint:
- A claimant typically pursues infringement by showing the accused product matches the crystalline Form N-2 definition by one of the permitted characterization methods (NMR and/or XRPD).
- A defendant typically attacks either:
- whether the accused product is actually Form N-2, or
- whether the measured peaks match within the stated tolerance windows.
The “at least one” analytical gate increases coverage
Because Claim 1 permits multiple independent identification routes, an accused manufacturer cannot avoid infringement merely because it differs in one analytical method, as long as it meets at least one of the enumerated criteria (NMR gate or XRPD gate or XRPD “FIG. 8” matching).
What does Claim 1 imply about legal claim construction?
The analytical parameters function like claim-defined structural limits
Even though polymorphs are not “structural formulas” in the chemical sense, Claim 1 uses defined physical measurements as a proxy for crystal structure. That matters because it creates claim boundaries that are measurable and testable:
- NMR gate: requires ≥4 peaks from a finite list at ±0.2 ppm and the peaks must be in a solid-state 13C NMR spectrum.
- XRPD gate: requires two specific peaks plus at least two additional peaks selected from a finite set, all at ±0.2° 2θ, and measurement at room temperature.
- FIG. 8 gate: invites expert comparison of patterns; “substantially in accordance with” tends to be litigated around degrees of match.
Room-temperature measurement is a constraint
The XRPD numeric gate expressly ties identification to room temperature, limiting the evidentiary framework for asserting Form N-2.
Form N-2: concrete numerical checkpoints
XRPD numeric checklist (CuKα λ=1.5418 Å)
To qualify under Claim 1(ii), the material must show:
| Peak type |
Requirement |
Tolerance |
| Anchor peaks |
20.9° 2θ |
±0.2° |
| Anchor peaks |
21.9° 2θ |
±0.2° |
| Additional peaks |
At least 2 peaks selected from list |
±0.2° |
Selectable additional peaks:
- 6.4, 9.1, 12.0, 12.8, 13.7, 17.1, 22.6, 23.7 (each ±0.2° 2θ)
Source: Claim 1(ii) per provided text.
Solid-state 13C NMR gate (peak presence test)
The material qualifies if the solid state 13C NMR spectrum contains at least four peaks (±0.2 ppm) from:
- 23.0, 25.9, 38.0, 41.7, 69.7, 102.0, 122.5, 177.3, 179.3, 180.0, 180.3.
Source: Claim 1(i) per provided text.
Medical-use scope: thyroid cancer and glioblastoma
Treatment coverage
The crystalline Form N-2 (L)-malate salt is used in:
- Thyroid cancer (Claim 3)
- including medullary thyroid cancer (Claim 5)
- Glioblastoma (Claim 4)
Claim language provided does not limit dosing, route, combination therapy, or specific patient characteristics beyond the cancer type subtype.
Patent landscape impact: what other products could still be “free”?
Without additional text you did not provide (e.g., other claims in the same family, earlier patents covering the base compound, later patents for other polymorphs/salts, or regulatory exclusivities), a robust landscape map cannot be completed to standard patent-analytics quality. The following landscape implications are limited to what can be logically concluded from the claim structure you supplied:
Non-infringing design spaces
A party could pursue potential non-infringement by selecting a different:
- salt form (Claim 1 is specifically (L)-malate)
- polymorph (Claim 1 is specifically crystalline Form N-2)
- crystalline material identity not matching the NMR or XRPD gates
- medical indication framing (claims are for thyroid cancer and glioblastoma; other indications are not expressly claimed here)
Infringing design pressure
If a competitor uses the same base API but manufactures Form N-2 (L)-malate, their product is exposed even if:
- their formulation uses different excipients (covered by Claim 2 only at composition level, but generally does not remove infringement risk on the API itself), or
- their use case remains within thyroid cancer/glioblastoma (covered by Claims 3 and 4).
Competitive assessment: why this claim pattern matters for R&D
Development and regulatory chemistry tradeoff
Because Claim 1 defines Form N-2 by analytical fingerprints, the key R&D lever is polymorph control and evidence generation:
- production routes that reliably yield Form N-2 will fall into the claim boundary
- routes that yield other polymorphs risk falling outside Claim 1, but only if the produced material does not meet the Claim 1 gate measurements
Litigation risk concentrates on characterization
The most direct infringement questions become:
- whether a submitted batch qualifies under NMR gate and/or XRPD numeric gate and/or FIG. 8 gate
- whether evidence supports room-temperature XRPD testing where applicable
Key Takeaways
- US 8,877,776 protects a single defined API entity: (L)-malate salt of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, limited to crystalline Form N-2.
- Claim 1 is polymorph-limited but characterization-permissive: Form N-2 qualifies if it matches any one of the three defined analytical criteria (solid-state 13C NMR, XRPD with explicit numeric peak targets, or XRPD substantially matching FIG. 8).
- Downstream claims extend to:
- a pharmaceutical composition containing Form N-2 (Claim 2), and
- methods for thyroid cancer (including medullary thyroid cancer) and glioblastoma (Claims 3-5).
- Practical infringement exposure hinges on whether an accused product is actually Form N-2, demonstrated against the claim’s ±0.2 ppm and ±0.2° 2θ tolerances and room-temperature XRPD condition.
FAQs
1) Does Claim 1 require all analytical tests to be met?
No. Claim 1 says Form N-2 is characterized by at least one of: (i) solid-state 13C NMR peak set, (ii) XRPD numeric pattern with anchor and selected additional peaks at room temperature, and/or (iii) XRPD substantially matching FIG. 8.
2) What are the XRPD anchor peaks for Form N-2 under Claim 1(ii)?
20.9 ± 0.2° 2θ and 21.9 ± 0.2° 2θ (CuKα λ=1.5418 Å), with at least two more peaks from the enumerated list.
3) How many 13C NMR peaks must appear under Claim 1(i)?
At least four peaks selected from the listed set, each at ±0.2 ppm.
4) Are formulations with different excipients still covered?
Claim 2 covers a pharmaceutical composition that includes the Claim 1 Form N-2 (L)-malate salt plus a pharmaceutically acceptable excipient. Changing excipients alone does not remove that composition claim linkage to the protected API form.
5) Which diseases are explicitly covered by method claims?
Thyroid cancer (including medullary thyroid cancer) and glioblastoma.
References
[1] Provided claim text for U.S. Patent 8,877,776 (claims 1-5), including Form N-2 characterization gates using solid-state 13C NMR, XRPD (CuKα λ=1.5418 Å; room temperature; specified peak tolerances), and XRPD substantially matching FIG. 8.
